Celdara Medical is focused on bringing the best innovations and discoveries out of leading academic labs and into human trials. We are currently developing multiple therapies spanning idiopathic pulmonary fibrosis, oncology, inflammation, transplantation, rare/orphan disease, and infectious disease. We currently have 20 employees and approximately 50 individuals engaged via contract or consulting agreements. We evaluate over 500 assets per year, yielding a robust and diverse early stage pipeline. We have affiliates in Seattle, WA (Virtici LLC), and Indianapolis, IN (MBV LLC), and offices in New York, DC, and Boston, and are working with researchers at over 50 leading research institutions across the country and internationally. We actively seek to exit our most advanced programs by employing partnership structures that best suit the asset and the parties.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
CM-YJ1 for Idiopathic Pulmonary Fibrosis
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):